These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2603505)

  • 21. [Direct reporting of side effects by the patient: favourable experience in the first year].
    van Grootheest AC; Passier JL; van Puijenbroek EP
    Ned Tijdschr Geneeskd; 2005 Mar; 149(10):529-33. PubMed ID: 15782689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 24. [Is establishment of causality in drug surveillance reliable?].
    Evreux JC
    Therapie; 1984; 39(4):437-8. PubMed ID: 6484888
    [No Abstract]   [Full Text] [Related]  

  • 25. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
    Lagier G; Vincens M; Castot A
    Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
    [No Abstract]   [Full Text] [Related]  

  • 26. [Necessity and difficulties of quantitative drug monitoring].
    Lagier G; Dally S; Vincens M; Castot A
    Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
    [No Abstract]   [Full Text] [Related]  

  • 27. [PSUR - Instrument for pharmacovigilance and patient safety. What pharmacists should know about periodic safety update reports].
    Strehl E
    Med Monatsschr Pharm; 2009 Sep; 32(9):347-9. PubMed ID: 19795697
    [No Abstract]   [Full Text] [Related]  

  • 28. Potential role of postmarketing research.
    Venulet J
    Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance].
    Stricker BH; Herings RM; Bakker A; Valkenburg HA; Sturmans F
    Ned Tijdschr Geneeskd; 1990 Sep; 134(39):1886-9. PubMed ID: 2215766
    [No Abstract]   [Full Text] [Related]  

  • 30. Communicating the risks and benefits of medicines.
    Schmid EF; Smith DA; Ryder SW
    Drug Discov Today; 2007 May; 12(9-10):355-64. PubMed ID: 17467571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations.
    Brown JS; Kulldorff M; Petronis KR; Reynolds R; Chan KA; Davis RL; Graham D; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):226-34. PubMed ID: 19148879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. With more follow-up.
    Prescrire Int; 2011 Feb; 20(113):32. PubMed ID: 21488585
    [No Abstract]   [Full Text] [Related]  

  • 33. [Evaluation of the therapeutic value of drugs--a task of clinical pharmacology].
    Herken H; Abshagen U
    Gynakologe; 1988 Mar; 21(1):14-20. PubMed ID: 3371753
    [No Abstract]   [Full Text] [Related]  

  • 34. A model for the future conduct of pharmacovigilance.
    Waller PC; Evans SJ
    Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 36. The yellow card: mark II.
    Lawson DH
    BMJ; 1990 Dec; 301(6763):1234. PubMed ID: 2271823
    [No Abstract]   [Full Text] [Related]  

  • 37. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 38. [Rapid drug information from the federal health office].
    Moll H
    Monatsschr Kinderheilkd; 1988 Jul; 136(7):400. PubMed ID: 3211173
    [No Abstract]   [Full Text] [Related]  

  • 39. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].
    Bégaud B; Evreux JC; Jouglard J; Lagier G
    Therapie; 1985; 40(2):111-8. PubMed ID: 4002188
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.